Faldaprevir

Research use only, not for human use.

A potent, selective noncovalent competitive inhibitor of HCV NS3/4A protease with Ki of 2.6 and 2.0 nM for GT1a and 1b NS3-NS4A protease, respectively.

A potent, selective noncovalent competitive inhibitor of HCV NS3/4A protease with Ki of 2.6 and 2.0 nM for GT1a and 1b NS3-NS4A protease, respectively; also shows Ki of 2 to 230 nM for HCV GT2 to 6, potently inhibits HCV RNA replication in vitro of 6.5 and 3.1 nM in genotype 1a and 1b replicon assays, respectively; possesses good ADME profile in vitro and pharmacokinetics in vivo.HCV Infection Phase 2 Clinical.

——

——

BI 201335 | BI201335 | BI-201335

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

801283-95-4

869.829

C40H49BrN6O9S

>98% (HPLC)

——

O=C([C@]1(NC([C@H]2N(C([C@@H](NC(OC3CCCC3)=O)C(C)(C)C)=O)C[C@H](OC4=CC(C5=CSC(NC(C(C)C)=O)=N5)=NC6=C(Br)C(OC)=CC=C46)C2)=O)[C@H](C=C)C1)O

(1R,2S)-1-[[(2S,4R)-4-[8-bromo-7-methoxy-2-[2-(2-methylpropanoylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-1-[(2S)-2-(cyclopentyloxycarbonylamino)-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-2 ethenylcyclopropane-1-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years